Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983853 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00983853 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 62 participants.
The verdict
NCT00983853, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).
Interventions
- BIOLOGICAL peginterferon alfa-2a
- DRUG telaprevir or matching placebo
- DRUG ribavirin (fixed dose)
- DRUG ribavirin (weight-based dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983853
The ClinicalTrials.gov registry entry for NCT00983853 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which peginterferon alfa-2a is the first listed.
NCT00983853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00983853 about?
NCT00983853 is a clinical study titled "Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV". The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).
What is the current status of trial NCT00983853?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2009-10.
What interventions are being tested in trial NCT00983853?
The interventions under investigation include: peginterferon alfa-2a (BIOLOGICAL), telaprevir or matching placebo (DRUG), ribavirin (fixed dose) (DRUG), ribavirin (weight-based dose) (DRUG).
Who is sponsoring clinical trial NCT00983853?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.